Definium Therapeutics (NASDAQ:DFTX) Insider Sells $513,845.07 in Stock

Key Points

• Insider sale: Mark Sullivan sold 14,051 Definium Therapeutics shares for approximately $513,845 under a pre-arranged Rule 10b5-1 trading plan, reducing his holdings by 2.76% to 494,228 shares.
• Stock and earnings: DFTX shares fell 0.5% to $38.21 in mid-day trading. The company reported a quarterly loss of $1.44 per share, missing the consensus estimate of a $0.55 loss.
• Analyst outlook: Despite one sell rating, most analysts maintain Buy or Strong Buy ratings, with a consensus price target of $64.88 versus the recent share price.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) insider Mark Sullivan sold 14,051 shares of the company's stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $513,845.07. Following the completion of the sale, the insider directly owned 494,228 shares in the company, valued at approximately $18,073,917.96. The trade was a 2.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Definium Therapeutics Trading Down 0.5%

Shares of Definium Therapeutics stock traded down $0.20 during mid-day trading on Tuesday, hitting $38.21. 1,967,182 shares of the stock were exchanged, compared to its average volume of 2,245,960. Definium Therapeutics, Inc. has a twelve month low of $10.46 and a twelve month high of $49.70. The stock has a market capitalization of $5.13 billion, a price-to-earnings ratio of -11.14 and a beta of 2.23. The company has a 50-day simple moving average of $41.37 and a 200 day simple moving average of $32.06. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Research analysts forecast that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.

Institutional Trading of Definium Therapeutics

Several large investors have recently modified their holdings of DFTX. Nykredit A S bought a new position in Definium Therapeutics in the 2nd quarter valued at about $45,000. Allworth Financial LP bought a new stake in shares of Definium Therapeutics during the 2nd quarter worth about $110,000. Integrated Wealth Concepts LLC bought a new stake in shares of Definium Therapeutics during the 2nd quarter worth about $159,000. NewEdge Advisors LLC acquired a new stake in shares of Definium Therapeutics in the 2nd quarter worth approximately $222,000. Finally, WINTON GROUP Ltd bought a new position in shares of Definium Therapeutics in the second quarter valued at approximately $240,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DFTX. Wall Street Zen downgraded Definium Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Wells Fargo & Company increased their target price on Definium Therapeutics from $68.00 to $72.00 and gave the stock an "overweight" rating in a research report on Thursday, August 13th. Robert W. Baird lifted their price target on Definium Therapeutics from $75.00 to $79.00 and gave the company an "outperform" rating in a report on Tuesday, September 15th. Canaccord Genuity Group set a $78.00 price objective on shares of Definium Therapeutics and gave the company a "buy" rating in a research note on Tuesday, September 15th. Finally, Bank of America began coverage on shares of Definium Therapeutics in a research report on Tuesday, August 18th. They issued a "buy" rating and a $75.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Definium Therapeutics currently has an average rating of "Buy" and a consensus target price of $64.88.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.